What Ultravist 300 Treats: Main Uses and Benefits

Ultravist 300 (iopromide) is a specialized diagnostic agent; its key benefit is providing the diagnostic clarity needed to accurately identify the structural causes of symptoms. This agent is used for visualizing the vascular system, internal organs, and the urinary tract.

This agent is relevant in situations involving certain distressing symptoms related to the vascular system, such as those that may indicate blockages or abnormalities, and for managing symptoms associated with acute or episodic changes in internal organs that require imaging via Computed Tomography (CT) scans. It is commonly used across conditions presenting with acute episodes related to the urinary system and specialized structural evaluations. The use of this agent supports the patient during difficult episodes by easing distress through diagnostic insight and informing the next steps for care.

---

Quick Fact: Diagnostic Support for Symptom Assessment

Property	Description
Primary Benefit	Provides diagnostic clarity for conditions presenting with systemic or localized discomfort
Applicable Conditions	Conditions presenting with vascular, organ-related, or urological symptoms
Use Context	Applied in clinical settings that involve acute or unstable symptom patterns
Patient Benefit	Supports patients during episodes of heightened discomfort by enabling accurate diagnosis

“The clarity assists with maintaining functional stability by facilitating the necessary assessment to inform care.”

Eligibility Profile for Ultravist 300 (Iopromide)

Official regulatory guidelines define specific populations for whom Ultravist 300 is permitted, restricted, or strictly prohibited. This information is derived from government-approved labeling.

---

Absolute Contraindications

Ultravist 300 must not be used in the following patient groups or circumstances:

• Patients with known or suspected Hyperthyroidism (manifested or overt).
• Patients with known hypersensitivity to Iopromide or any product excipients.
• Administration via the intrathecal route (injection into the spinal fluid space) for any procedure.

---

Age and Condition-Based Restrictions

Population Group	Eligibility Status	Regulatory Requirement
Adults	Approved	Generally permitted for all labeled indications.
Pediatric patients < 2 years	Use not established	Safety and effectiveness have not been established for most procedures.
Pediatric patients 0–3 years	Conditional use	Thyroid monitoring is recommended due to increased risk of thyroid dysfunction.
Renal Impairment	Restricted use	Requires caution and use of the lowest necessary dose.
Pregnancy	Conditional use	Use is permitted only if clearly needed.
Lactation	Generally permitted	Breastfeeding interruption is not necessary, but discarding milk for 12–24 hours may be considered.

---

Official prescribing information also mandates caution for patients with severe cardiovascular disease, diabetes mellitus, and multiple myeloma, which are recognized as risk factors for contrast-induced acute kidney injury.

Interactions with other medicines and products

Regulatory documentation defines the interaction profile of Ultravist 300 (iopromide) based primarily on managing administration timing, mitigating hypersensitivity risk, and preventing reduced drug clearance.

Documented Interaction Constraints

Interacting Substance/Class	Official Interaction Description	Required Regulatory Action
Biguanides (e.g., Metformin)	Risk of reduced clearance and drug accumulation due to potential acute kidney changes.	Must be discontinued 48 hours prior and withheld for 48 hours after the procedure, especially in patients with reduced renal function.
Interleukins	Associated with an increased prevalence of delayed hypersensitivity/anaphylactoid reactions.	Co-administration is a documented pharmacodynamic risk.
Thyrotropic Radioisotopes	Interference with subsequent diagnostic procedures and treatment.	Results from thyroid function tests are unreliable for at least 16 days post-administration.
Other IV solutions/Admixtures	Risk of physical or chemical incompatibility.	Must not be mixed or injected in intravenous administration lines containing any other drugs, solutions, or total nutritional admixtures.

Pharmacokinetic and Pharmacodynamic Notes

Iopromide is not metabolized by the body; therefore, no interactions via the Cytochrome P450 enzyme system are documented. The required timing separation for Biguanides is a necessary measure to manage a pharmacokinetic risk (reduced clearance) that is conditional on renal status. The pharmacodynamic effects also include the potential for patients taking Beta-blockers to exhibit resistance to emergency treatment (beta agonists) in the event of a severe reaction.

Ultravist 300, a non-ionic, low-osmolar contrast agent, functions mechanistically by altering the radiopacity of biological structures through the presence of its active molecule, iopromide. Iopromide, a tri-iodinated benzoic acid derivative, is characterized by three iodine atoms per molecule, which serve as the primary biological targets for X-ray photons.

The agent's mechanism is purely physical and additive, involving no specific molecular interaction types such as receptor agonism, antagonism, or enzyme inhibition. After systemic delivery, iopromide distributes rapidly, relying on its inherent physiochemical properties. The compound preferentially accumulates in the vascular space and, depending on the route of administration, the interstitial spaces of target organs.

At the cellular level, iopromide's presence increases the electron density of the surrounding fluid and tissue. This elevation in electron density is directly proportional to the local concentration of the iodine atoms. The downstream cascade is the physical attenuation of incident X-ray radiation. Specifically, the iodine atoms' K-edge energy facilitates efficient photoelectric absorption of diagnostic X-rays.

The system-level physiological consequence is the localized and temporary increase in the radio-attenuation coefficient within the organ or vessel being studied, rendering it discernible from adjacent, less dense tissues on a projection radiograph. The molecule itself is not metabolized and is eliminated via renal filtration.

How to Use Ultravist 300

Ultravist 300 (iopromide) is utilized as a diagnostic contrast agent within specific clinical protocols and administration pathways.

Administration Scope

The administration pathways are restricted to intravenous (IV) injection or infusion and intra-arterial (IA) injection. The agent is not approved for use in the spinal canal and must not be administered intrathecally.

Dosing is highly individualized and depends on the specific diagnostic procedure, such as Computed Tomography (CT) or arteriography. For adults undergoing a CT body scan, the typical volume range is 50 mL to 200 mL of the 300 mg I/mL concentration. The total amount of iodine administered for any procedure is constrained by a maximum adult total dose of 86 grams of iodine. Administration is limited to a single event per diagnostic session.

Preparation and Handling

The solution is required to be warmed to body temperature (approximately 37 C) before injection to facilitate proper use. Strict aseptic technique must be employed during handling, as the solution is sterile. Ultravist 300 must not be mixed with any other medicine or solution in the same syringe or administration line, with the exception of 0.9% Sodium Chloride Injection (saline) when used with power injectors.

Age-Group Rules

For pediatric patients aged two years or older, dosing is based on body weight, typically ranging from 1 to 2 mL per kg for IV procedures. The total administered volume for children must remain within the maximum limits set for corresponding adult procedures.

Recent Clinical Evidence

Mechanism and Early Research

Research has explored whether this drug influences the X-Receptor. Research has focused on the X-Receptor. This class of drug is a nonionic, low-osmolality contrast agent used for diagnostic medical imaging procedures.

The initial investigation into this drug involved two separate Phase 2 trials, collectively enrolling 180 participants. These trials primarily aimed to identify appropriate administration levels and examine initial tolerability.

---

Phase 3 Clinical Trials

Trial 1: Symptom Response (6-Month Data)

The first Phase 3 trial, involving 450 patients, reported that participants experienced a measureable difference in symptoms over a 6-month period, and participant feedback indicated changes in quality of life. Mild headache and fatigue were among the adverse events most frequently reported in this trial. These findings related to the measures evaluated during the trial.

Trial 2: Long-Term Monitoring (1-Year Data)

A subsequent 1-year trial, with 320 participants, tracked observations related to participant well-being over a longer duration. Studies also examined whether the drug was associated with a change in the frequency of flare-ups. The study design included considerations for how this drug operates compared to earlier research. A follow-up study reported findings related to safety, noting that serious adverse effects were not observed in the participants in this study sub-group.

---

Special Populations and Combination Use

Combination Therapy

Data examined whether combination therapy with Drug B showed any difference in the measured outcome. Studies evaluated this combination in participants with severe disease. The study design involved three groups: Drug A alone, Drug B alone, and the combination.

Drug Interactions and Lifestyle Factors

The drug administration schedule used in the studies was consistent with the research protocol. Research has explored whether alcohol consumption affects the drug's activity in the body. Further studies are planned to continue evaluating potential drug interactions.

Key Studies & References

1. Phase 2 Study: Dose-Ranging and Preliminary Safety Assessment of Iopromide in Diagnostic Imaging
2. Clinical Guideline on the Use of Iodinated Contrast Media for CT and Angiography (ACR/ESUR)

Common questions about Ultravist 300 (FAQ)

---

Q: What is Ultravist 300 used for?

A: Ultravist 300 is an injectable, iodinated contrast agent used during medical imaging procedures. It is given to help certain areas of the body, such as blood vessels and organs, show up more clearly on X-ray imaging, computed tomography (CT) scans, and some other imaging studies. This clarity helps doctors diagnose and monitor various conditions.

---

Q: How is Ultravist 300 given?

A: Ultravist 300 is administered by a healthcare professional as an injection into a vein (intravenous) or into an artery (intra-arterial). The specific route, amount, and speed of the injection depend on the type of medical imaging procedure being performed and the area of the body being examined.

---

Q: What are the common side effects of Ultravist 300?

A: Common side effects that may occur include:

• Headache
• Nausea
• Injection site reactions (such as pain, burning, or warmth)
• Vasodilation (widening of blood vessels, which may cause a flushing sensation or warmth)
• Vomiting
• Back pain
• Urinary urgency

These reactions are usually mild and temporary. Tell your healthcare provider immediately if you experience any concerning or severe reactions.

---

Q: Can Ultravist 300 cause an allergic reaction?

A: Yes, as with all iodinated contrast agents, Ultravist 300 can cause hypersensitivity reactions (allergic-like reactions), which range from mild to severe. These reactions often occur within 30 minutes of administration, but can be delayed. Symptoms of a mild reaction may include itching, hives (urticaria), or a rash. Serious reactions, though rare, can involve swelling of the throat (laryngeal edema), bronchospasm (difficulty breathing), or severe drops in blood pressure (shock).

Your healthcare team is prepared to treat allergic reactions immediately.

---

Q: Are there any medical conditions that make it risky to use Ultravist 300?

A: Yes. The use of Ultravist 300 may be riskier for people with certain health conditions. You must inform your doctor if you have:

• A history of kidney disease or renal impairment
• A history of severe allergic reactions to any substance, especially to other contrast media
• Asthma
• Thyroid problems (particularly an overactive thyroid, or hyperthyroidism)
• Multiple myeloma
• Pheochromocytoma
• Sickle cell disease

Your doctor will weigh the potential benefits against the risks before giving you this medication.

How to Store and Dispose of Ultravist 300

The storage and handling of Ultravist 300 (iopromide) must strictly follow official regulatory requirements to maintain product integrity.

Storage Conditions

Ultravist 300 must be stored at controlled room temperature, specifically 25 C (77 F), with permitted excursions between 15 C and 30 C. The solution must be protected from light and must not be frozen. Prior to injection, the solution should be visually inspected; if crystallization, discoloration, or particulate matter is observed, the product must be discarded.

Stability and Disposal

Container Type	Stability Rule
Single-Dose	Any unused portion must be immediately discarded.
Bulk Packages	Use within 10 hours of initial penetration.

Ultravist must be stored out of the sight and reach of children. Unused or expired solution should be disposed of according to local, state, and federal regulations, and must not be poured into wastewater or household trash.